Mr. Marc Lemieux reports

KDA GROUP LAUNCHES MEDHERIZE FOR SPECIALIZED METASTATIC BREAST CANCER TREATMENT MANAGEMENT

KDA Group Inc. has launched Medherize, an innovative initiative to improve the management of specialized treatments for metastatic breast cancer. Developed in collaboration with doctors, pharmacists and patients, this platform aims to enhance the quality of care and support for health care professionals and patients.

Support for health care professionals

Medherize helps health care professionals better manage treatments for patients with breast cancer. The platform offers tools to track treatment adherence, manage side effects and optimize care plans, facilitating an integrated and personalized approach.

Impact on patients

Medherize provides patients with clear information about their treatments, reminders for appointments and medications, and access to support resources, helping them feel more autonomous and supported in their fight against cancer.

Current challenges in breast cancer treatment and patient journey

Current challenges include limited resources and support for patients, high risk of treatment dropouts, delays in obtaining results, medication adherence issues, complex follow-up schedules and a high potential for errors. Medherize addresses these issues by offering an integrated and efficient solution to improve the patient journey and quality of care.

Statistics on metastatic breast cancer

In 2024, approximately 30,500 new cases of breast cancer will be diagnosed among women in Canada, with 15 per cent progressing to metastatic form.

In the United States, about 155,000 women are living with metastatic breast cancer, with 168,000 new cases diagnosed each year.

These figures highlight the importance of prevention, early detection and research to improve treatment and the quality of life for patients.

Economy and efficiency

The adoption of Medherize not only aims to improve care but also to bring economic benefits to the Canadian and American health care systems. By optimizing treatment management and reducing hospitalizations and complications, Medherize contributes to more efficient use of health care resources.

Collaboration for the future

"At KDA, we firmly believe that collaboration is key to improving health care," said Marc Lemieux, chief executive officer of KDA. "With Medherize, we unite our efforts with health care professionals and patients to create a solution that not only meets current medical needs but also anticipates future challenges. We are confident that this initiative will positively transform the landscape of breast cancer treatment management."

Finally, the corporation announces that, in accordance with its stock option plan, it has granted incentive stock options to directors, officers, employees and consultants of the corporation for the purchase of up to 14.6 million Class A shares. The stock options may be exercised no later than Aug. 1, 2029, at a price of 30 cents per common share, are subject to a 12-month vesting period and vest one-quarter on the grant date and three quarters on the first anniversary of the grant date. The stock options are granted in accordance with the TSX Venture Exchange's policies and the terms and conditions of the corporation's stock option plan.

About KDA Group Inc.

KDA Group is a leader in technological innovations and specialized software solutions (SaaS -- software-as-a-service) for the health care professionals' market. KDA is a corporation that offers quality products and has a respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the health care's digital transformation, and are available for the Canadian and international markets.

We seek Safe Harbor.